Johnson & Johnson has confirmed that the Laminar LAAX IDE trial has voluntarily been paused, which should cause a delay in the trial completion, Wells Fargo tells investors in a research note. Johnson & Johnson says the decision to pause the trial follows isolated reports of unwrapping, and says a comprehensive evaluation of all device sizes and associated clinical data is underway. Wells Fargo has an Equal Weight rating and $152 price target on J&J shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
- J&J’s ‘968 delay has mixed readthroughs for Incyte’s ‘989, says RBC
- Johnson & Johnson announces new data presented at EAN of IMAAVY
- Johnson & Johnson launches ACUVUE OASYS in U.S., Canada
- Johnson & Johnson to pay $8M in Massachusetts mesothelioma talc lawsuit